Curcumin Attenuates Acute Graft-versus-Host Disease Severity via In Vivo Regulations on Th1, Th17 and Regulatory T Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Park, Min Jung ^a   Moon, Su Jin ^b   Lee, Sung Hee ^a   Yang, Eun Ji ^a   Min, Jun Ki ^b   Cho, Seok Goo ^b   Yang, Chul Woo ^c   Park, Sung Hwan ^a   Kim, Ho Youn ^a   Cho, Mi La ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; GAMMA INTERFERON; INTERLEUKIN 17; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL POPULATION; CELL SUBPOPULATION; COLON DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; HOMEOSTASIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE EPITHELIUM; LIVER DISEASE; LUNG DISEASE; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; SKIN; SKIN DISEASE; SKIN EPITHELIUM; SPLEEN CELL; TH1 CELL; TH17 CELL; TREATMENT OUTCOME;

ANIMALS; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELLS, CULTURED; COLON; CURCUMIN; GRAFT VS HOST DISEASE; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-17; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SKIN; SPLEEN; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TRANSCRIPTION FACTOR AP-1;

ANIMALIA; MURINAE; MUS;

EID: 84879265773     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067171     Document Type: Article

References (53)

1. Pasquini MC, Wang Z, Horowitz MM, Gale RP (2010) 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl: 87-105.
2. Bolanos-Meade J, (2006) Update on the management of acute graft-versus-host disease. Curr Opin Oncol 18: 120-125.
3. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, et al. (2002) Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 8: 387-394.
4. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, et al. (1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76: 1464-1472.
5. Ferrara JL, Levine JE, Reddy P, Holler E, (2009) Graft-versus-host disease. Lancet 373: 1550-1561.
6. Lu Y, Waller EK, (2009) Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant 15: 1347-1353.
7. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, et al. (1998) Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 102: 1882-1891.
8. Blazar BR, Murphy WJ, Abedi M, (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12: 443-458.
9. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, et al. (2009) In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113: 1365-1374.
10. Ukena SN, Grosse J, Mischak-Weissinger E, Buchholz S, Stadler M, et al. (2011) Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells. Ann Hematol 90: 213-218.
11. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, et al. (2010) Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 16: 907-914.
12. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, et al. (2011) Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 118: 2342-2350.
13. Duramad O, Laysang A, Li J, Ishii Y, Namikawa R, (2011) Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant 17: 1154-1168.
14. Kroger N, Zabelina T, Kruger W, Renges H, Stute N, et al. (2002) In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 29: 683-689.
15. Ali T, Shakir F, Morton J, (2012) Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion 85: 249-255.
16. Aggarwal BB, Harikumar KB, (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41: 40-59.
17. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R, (1995) Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94: 79-83.
18. Ramsewak RS, DeWitt DL, Nair MG, (2000) Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine 7: 303-308.
19. Apisariyakul A, Vanittanakom N, Buddhasukh D, (1995) Antifungal activity of turmeric oil extracted from Curcuma longa (Zingiberaceae). J Ethnopharmacol 49: 163-169.
20. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK, (1999) Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 47: 4297-4300.
21. Xie L, Li XK, Funeshima-Fuji N, Kimura H, Matsumoto Y, et al. (2009) Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 9: 575-581.
22. Zhang M, Deng CS, Zheng JJ, Xia J, (2006) Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 27: 1071-1077.
23. Fukui J, Inaba M, Ueda Y, Miyake T, Hosaka N, et al. (2007) Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. Stem Cells 25: 1595-1601.
24. Zhou H, Beevers CS, Huang S, (2011) The targets of curcumin. Curr Drug Targets 12: 332-347.
25. Baumeister P, Reiter M, Harreus U, (2012) Curcumin and other polyphenolic compounds in head and neck cancer chemoprevention. Oxid Med Cell Longev 2012: 902716.
26. Zandi K, Ramedani E, Mohammadi K, Tajbakhsh S, Deilami I, et al. (2010) Evaluation of antiviral activities of curcumin derivatives against HSV-1 in Vero cell line. Nat Prod Commun 5: 1935-1938.
27. Xiao X, Yang M, Sun D, Sun S, (2012) Curcumin protects against sepsis-induced acute lung injury in rats. J Surg Res 176: e31-39.
28. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, et al. (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102: 756-762.
29. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, et al. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285: 412-415.
30. Krenger W, Ferrara JL, (1996) Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 15: 50-73.
31. Teshima T, Maeda Y, Ozaki K, (2011) Regulatory T cells and IL-17-producing cells in graft-versus-host disease. Immunotherapy 3: 833-852.
32. Kang BY, Song YJ, Kim KM, Choe YK, Hwang SY, et al. (1999) Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol 128: 380-384.
33. Cong Y, Wang L, Konrad A, Schoeb T, Elson CO, (2009) Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells. Eur J Immunol 39: 3134-3146.
34. Janssens W, Carlier V, Wu B, VanderElst L, Jacquemin MG, et al. (2003) CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 171: 4604-4612.
35. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL, (2002) CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 196: 401-406.
36. Zhao D, Zhang C, Yi T, Lin CL, Todorov I, et al. (2008) In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 112: 2129-2138.
37. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, et al. (2004) Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 104: 1565-1573.
38. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, et al. (2004) Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104: 2187-2193.
39. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, et al. (2005) Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106: 2903-2911.
40. Zhao GJ, Lu ZQ, Tang LM, Wu ZS, Wang DW, et al. (2012) Curcumin inhibits suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. Int Immunopharmacol 14: 99-106.
41. Dhandapani KM, Mahesh VB, Brann DW, (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102: 522-538.
42. Sviland L, Pearson AD, Eastham EJ, Green MA, Hamilton PJ, et al. (1988) Class II antigen expression by keratinocytes and enterocytes-an early feature of graft-versus-host-disease. Transplantation 46: 402-406.
43. Bland PW, Whiting CV, (1992) Induction of MHC class II gene products in rat intestinal epithelium during graft-versus-host disease and effects on the immune function of the epithelium. Immunology 75: 366-371.
44. Kim BS, Miyagawa F, Cho YH, Bennett CL, Clausen BE, et al. (2009) Keratinocytes function as accessory cells for presentation of endogenous antigen expressed in the epidermis. J Invest Dermatol 129: 2805-2817.
45. Schattenfroh NC, Hoffman RA, McCarthy SA, Simmons RL, (1995) Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease. Transplantation 59: 268-273.
46. Young JS, Wu T, Chen Y, Zhao D, Liu H, et al. (2012) Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol 189: 222-233.
47. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, et al. (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111: 5530-5536.
48. Korwek Z, Bielak-Zmijewska A, Mosieniak G, Alster O, Moreno-Villanueva M, et al. (2013) DNA damage-independent apoptosis induced by curcumin in normal resting human T cells and leukaemic Jurkat cells. Mutagenesis.
49. Alizadeh AM, Khaniki M, Azizian S, Mohaghgheghi MA, Sadeghizadeh M, et al. (2012) Chemoprevention of azoxymethane-initiated colon cancer in rat by using a novel polymeric nanocarrier-curcumin. Eur J Pharmacol 689: 226-232.
50. Vishvakarma NK, Kumar A, Singh SM, (2011) Role of curcumin-dependent modulation of tumor microenvironment of a murine T cell lymphoma in altered regulation of tumor cell survival. Toxicol Appl Pharmacol 252: 298-306.
51. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S, (1999) Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 93: 152-161.
52. Hayun R, Okun E, Berrebi A, Shvidel L, Bassous L, et al. (2009) Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leuk Lymphoma 50: 625-632.
53. Huang G, Yang Y, Xu Z, Zhou P, Gong W, et al. (2011) Downregulation of B lymphocyte stimulator expression by curcumin in B lymphocyte via suppressing nuclear translocation of NF-kappaB. Eur J Pharmacol 650: 451-457.